Literature DB >> 10674280

Hormonal markers of stress response following interruption of selective serotonin reuptake inhibitor treatment.

D Michelson1, J Amsterdam, J Apter, M Fava, P Londborg, R Tamura, L Pagh.   

Abstract

Depressive illness is associated with loss of the usual regulation of stress-responsive hormonal and neurotransmitter systems, and antidepressants have intrinsic effects reducing the activity of these systems. Abrupt interruption of treatment with some antidepressants has been associated with a self-limited syndrome of physical and psychological symptoms distinct from relapse, of which drug half-life appears to be the major determinant. We hypothesized that reactivation of stress-response systems could play a role in this syndrome and studied the effects of treatment interruption in patients successfully treated with the antidepressant fluoxetine, paroxetine or sertraline. During placebo substitution, interruption of paroxetine was associated with statistically significant increases in plasma IGF-1 and heart rate. These data suggest that some activation of physiologic stress-responses may accompany symptom increases during treatment interruption of shorter half-life agents.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10674280     DOI: 10.1016/s0306-4530(99)00046-3

Source DB:  PubMed          Journal:  Psychoneuroendocrinology        ISSN: 0306-4530            Impact factor:   4.905


  7 in total

Review 1.  Antidepressant Withdrawal and Rebound Phenomena.

Authors:  Jonathan Henssler; Andreas Heinz; Lasse Brandt; Tom Bschor
Journal:  Dtsch Arztebl Int       Date:  2019-05-17       Impact factor: 5.594

2.  Pathophysiology of hypercortisolism in depression: pituitary and adrenal responses to low glucocorticoid feedback.

Authors:  B J Carroll; A Iranmanesh; D M Keenan; F Cassidy; W H Wilson; J D Veldhuis
Journal:  Acta Psychiatr Scand       Date:  2011-12-30       Impact factor: 6.392

Review 3.  Role of trophic factors GDNF, IGF-1 and VEGF in major depressive disorder: A comprehensive review of human studies.

Authors:  Ajaykumar N Sharma; Bruno Fernando Borges da Costa e Silva; Jair C Soares; André F Carvalho; Joao Quevedo
Journal:  J Affect Disord       Date:  2016-03-02       Impact factor: 4.839

4.  Psychopharmacology of maternal separation anxiety in vervet monkeys.

Authors:  Lelanie Marais; Willie Daniels; Linda Brand; Francois Viljoen; Charmaine Hugo; Dan J Stein
Journal:  Metab Brain Dis       Date:  2006-07-19       Impact factor: 3.584

5.  Course of illness, hippocampal function, and hippocampal volume in major depression.

Authors:  Glenda M MacQueen; Stephanie Campbell; Bruce S McEwen; Kathryn Macdonald; Shigeko Amano; Russell T Joffe; Claude Nahmias; L Trevor Young
Journal:  Proc Natl Acad Sci U S A       Date:  2003-01-24       Impact factor: 11.205

Review 6.  Insulin-like growth factor-1: a possible marker for emotional and cognitive disturbances, and treatment effectiveness in major depressive disorder.

Authors:  Oleg A Levada; Alexandra S Troyan
Journal:  Ann Gen Psychiatry       Date:  2017-10-26       Impact factor: 3.455

7.  The mechanisms by which antidepressants may reduce coronary heart disease risk.

Authors:  Marc J Mathews; Edward H Mathews; Leon Liebenberg
Journal:  BMC Cardiovasc Disord       Date:  2015-08-01       Impact factor: 2.298

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.